Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cellectis S.A. ADR (CLLS)

Cellectis S.A. ADR (CLLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 266,228
  • Shares Outstanding, K 55,580
  • Annual Sales, $ 49,220 K
  • Annual Income, $ -36,760 K
  • EBIT $ -26 M
  • EBITDA $ -7 M
  • 60-Month Beta 2.81
  • Price/Sales 6.44
  • Price/Cash Flow N/A
  • Price/Book 2.59

Options Overview Details

View History
  • Implied Volatility 70.99% (-329.53%)
  • Historical Volatility 102.31%
  • IV Percentile 1%
  • IV Rank 0.00%
  • IV High 1,033.35% on 11/11/25
  • IV Low 70.99% on 12/16/25
  • Expected Move (DTE 3) 0.59 (14.30%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 12
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 828
  • Open Int (30-Day) 845
  • Expected Range 3.51 to 4.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +434,447.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.90 +2.56%
on 11/18/25
5.45 -26.61%
on 12/11/25
+0.10 (+2.56%)
since 11/14/25
3-Month
2.48 +61.23%
on 09/29/25
5.48 -27.00%
on 10/16/25
+0.84 (+26.58%)
since 09/16/25
52-Week
1.10 +263.64%
on 04/07/25
5.48 -27.00%
on 10/16/25
+2.27 (+131.21%)
since 12/16/24

Most Recent Stories

More News
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan...

ALLO : 1.4550 (-1.02%)
CLLS : 4.03 (-15.87%)
Cellectis Announces Arbitral Decision in Dispute with Servier

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...

CLLS : 4.03 (-15.87%)
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapy In vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion...

CLLS : 4.03 (-15.87%)
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...

CLLS : 4.03 (-15.87%)
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with...

CLLS : 4.03 (-15.87%)
Cellectis to Present a Development Update for eti-cel at ASH 2025

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHL Preclinical data demonstrated that combining...

CLLS : 4.03 (-15.87%)
Cellectis to Report Third Quarter Financial Results on November 7, 2025

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...

CLLS : 4.03 (-15.87%)
Cellectis Showcases Pipeline Progress at R&D Day

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cellectis...

CLLS : 4.03 (-15.87%)
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL

  ○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety:  in Phase 1 (n=40), lasme-cel was generally well-tolerated...

CLLS : 4.03 (-15.87%)
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth:...

CLLS : 4.03 (-15.87%)

Business Summary

Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.

See More

Key Turning Points

3rd Resistance Point 5.29
2nd Resistance Point 5.10
1st Resistance Point 4.94
Last Price 4.03
1st Support Level 4.59
2nd Support Level 4.40
3rd Support Level 4.24

See More

52-Week High 5.48
Last Price 4.03
Fibonacci 61.8% 3.81
Fibonacci 50% 3.29
Fibonacci 38.2% 2.77
52-Week Low 1.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar